License and Collaboration Agreements - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2025	Jun. 30, 2024	Jun. 30, 2025	Jun. 30, 2024	Dec. 31, 2024
License And Collaboration Agreements [Line Items]
Research and development costs	$ 61,030	$ 36,259	$ 102,489	$ 66,905
General and administrative expense	14,768	13,768	28,305	26,111
Genrix License Agreement \| Research and Development
License And Collaboration Agreements [Line Items]
Upfront license fee	20,000		$ 20,000
Pearl - Taiho
License And Collaboration Agreements [Line Items]
Percentage of profits from potential sales			50.00%
Research and development expense related to share of costs	7,800	5,200	$ 13,400	11,200
Accrued expenses and other current liabilities	5,300		5,300		$ 6,000
RecievablesFromRelatedParty	130,000		130,000
Research and development costs	3,100	$ 2,800	4,500	$ 4,700
General and administrative expense	$ 600		1,100
Genrix Biopharmaceutical Co, Ltd \| Genrix License Agreement
License And Collaboration Agreements [Line Items]
Upfront license fee			20,000
Genrix Biopharmaceutical Co, Ltd \| Maximum \| Genrix License Agreement
License And Collaboration Agreements [Line Items]
Milestone payments			292,000
Genrix Biopharmaceutical Co, Ltd \| Maximum \| Genrix License Agreement \| Sales Based [Member]
License And Collaboration Agreements [Line Items]
Milestone payments			$ 400,000